| Dr Philip Alan Scolaro, MD | |
|
3802 22nd St, Suite 200, Lubbock, TX 79410-1107 | |
| (806) 791-0188 | |
| (806) 788-0470 |
| Full Name | Dr Philip Alan Scolaro |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 39 Years |
| Location | 3802 22nd St, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609961812 | NPI | - | NPPES |
| 120401803 | Medicaid | TX | |
| 8CD477 | Other | TX | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | H0799 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Covenant Medical Center | Lubbock, TX | Hospital |
| Covenant Childrens Hospital | Lubbock, TX | Hospital |
| University Medical Center | Lubbock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ear Nose And Throat Associates Of Lubbock Pa | 6103968896 | 2 |
News Archive
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called "blurring", may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, such as multiple sclerosis.
In the lead-up to Rare Diseases Day – on Sunday February 28 - Associate Professor Kim Hemsley's studies into childhood dementia are helping to unlock answers that can assist treatment of these largely unheralded conditions.
SapientNitro, part of Sapient, today announced the launch of Spokes of Change, an anti-poverty campaign and fundraising effort initiated by the eminent international non-profit organization, Millennium Promise.
To realize precise diagnosis of early-stage cancer for effective treatment and better prognosis, high-resolution magnetic resonance imaging (MRI) is indispensable with the help of contrast agents.
› Verified 6 days ago
| Entity Name | Ear Nose And Throat Associates Of Lubbock Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790019784 PECOS PAC ID: 6103968896 Enrollment ID: O20100119000231 |
News Archive
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called "blurring", may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, such as multiple sclerosis.
In the lead-up to Rare Diseases Day – on Sunday February 28 - Associate Professor Kim Hemsley's studies into childhood dementia are helping to unlock answers that can assist treatment of these largely unheralded conditions.
SapientNitro, part of Sapient, today announced the launch of Spokes of Change, an anti-poverty campaign and fundraising effort initiated by the eminent international non-profit organization, Millennium Promise.
To realize precise diagnosis of early-stage cancer for effective treatment and better prognosis, high-resolution magnetic resonance imaging (MRI) is indispensable with the help of contrast agents.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip Alan Scolaro, MD 3802 22nd St, Suite 200, Lubbock, TX 79410-1107 Ph: (806) 791-0188 | Dr Philip Alan Scolaro, MD 3802 22nd St, Suite 200, Lubbock, TX 79410-1107 Ph: (806) 791-0188 |
News Archive
REGENERX BIOPHARMACEUTICALS, INC. announced today that it has completed and analyzed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. The trial included testing of a single escalating intravenous dose of the drug candidate on forty healthy volunteers in Phase IA and, subsequently, over a fourteen-day treatment period on forty volunteers in Phase IB.
Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called "blurring", may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, such as multiple sclerosis.
In the lead-up to Rare Diseases Day – on Sunday February 28 - Associate Professor Kim Hemsley's studies into childhood dementia are helping to unlock answers that can assist treatment of these largely unheralded conditions.
SapientNitro, part of Sapient, today announced the launch of Spokes of Change, an anti-poverty campaign and fundraising effort initiated by the eminent international non-profit organization, Millennium Promise.
To realize precise diagnosis of early-stage cancer for effective treatment and better prognosis, high-resolution magnetic resonance imaging (MRI) is indispensable with the help of contrast agents.
› Verified 6 days ago
Dr. John R. Marchbanks, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 3502 9th St, Suite 410, Lubbock, TX 79415 Phone: 806-743-4115 Fax: 806-743-1313 | |
Dr. Thomas F Neal, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 3621 22nd St, Ste 300, Lubbock, TX 79410 Phone: 806-792-5331 Fax: 806-792-9417 | |
Joshua Charles Demke, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St Fl 4, Lubbock, TX 79430 Phone: 806-743-2373 Fax: 806-743-4354 | |
Dr. William Russell Fell, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3802 22nd, #100, Lubbock, TX 79410 Phone: 806-792-5331 Fax: 806-792-9417 | |
Dr. Joehassin Cordero, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3502 9th St, Suite 410, Lubbock, TX 79415 Phone: 806-743-4115 Fax: 806-743-1313 | |
Tam Nguyen, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3502 9th St, Ste 410, Lubbock, TX 79415 Phone: 806-743-4115 Fax: 806-743-1313 | |
Yusuf Dundar, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-4115 Fax: 806-743-2374 |